Sintilimab: A Promising Anti-Tumor PD-1 Antibody, PMID: 33324564
Sintilimab: First Global Approval, PMID: 30742278
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC, PMID: 32036071
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11), PMID: 32781263
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit, PMID: 31402780
Recent updates on Sintilimab in solid tumor immunotherapy, PMID: 33292551
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial, PMID: 30612710
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients, PMID: 33241036
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial, PMID: 32795349
Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11), PMID: 33246599
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study, PMID: 33070260
Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer, PMID: 32981596
Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression, PMID: 32973816
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab, PMID: 32304999
Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma, PMID: 30612711
Antibodies to watch in 2019, PMID: 30516432
Sintilimab as salvage treatment in an HIV patient with relapsed/refractory Hodgkin: a case report, PMID: 32692239
Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature, PMID: 33194584
Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review, PMID: 33363038
Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report, PMID: 32656988
Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab, PMID: 32662522
Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review, PMID: 34106616
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12), PMID: 34048947
Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis, PMID: 32386943
Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients, PMID: 32627214
Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report, PMID: 32481252
Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy, PMID: 32109851
Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature, PMID: 33545801
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies, PMID: 31362369
The binding epitope of sintilimab on PD-1 revealed by AbMap, PMID: 33637989
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study, PMID: 34143971
Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report, PMID: 32233637
Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma, PMID: 32309397
Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients, PMID: 32643323
Sintilimab in Treating Advanced Lung Squamous Cell Carcinoma After Fourth-Line Treatment of Anlotinib Resistance, PMID: 34145167
Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, December 2020, Page S1428], PMID: 33736838
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC, PMID: 33524601
Fasciitis induced by sintilimab in a patient with recurrent hepatocellular carcinoma, PMID: 34364744
Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report, PMID: 34338239
The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China, PMID: 33928222
Effect of Sintilimab combined with Chemotherapy on Tumor Markers and Immune Function of advanced non-small cell lung cancer, PMID: 34290784
RETRACTED: ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC), PMID: 33517977
Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation, PMID: 34109111
Discovery of New Immune Checkpoints: Family Grows Up, PMID: 32185707
A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient: A case report, PMID: 34397833
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study, PMID: 34358724
Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report, PMID: 33725836
Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report, PMID: 33949137
Pazopanib together with 6-8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma, PMID: 34159088
A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report, PMID: 33907417
Successful resection of a huge hepatocellular carcinoma during pregnancy: case report and review of the literature., PMID:40518467
Severe immunotherapy-related thrombocytopenia in metastatic bone cancer: a multicenter retrospective case series highlighting early recognition and management., PMID:40496609
Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report., PMID:40496608
Research progress of sintilimab in the treatment of cancer (Review)., PMID:40486088
Combination therapy of TKIs and ICIs for the treatment of anaplastic thyroid carcinoma., PMID:40485736
Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report., PMID:40481624
Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis., PMID:40481442
Stevens-Johnson syndrome induced by Sintilimab: a case report and literature review., PMID:40475009
Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)., PMID:40475000
Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study., PMID:40472923
Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer., PMID:40469279
Neoadjuvant chemotherapy or chemoradiotherapy plus sintilimab versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a study protocol of a multicentre, randomised, controlled, phase III trial (SCIENCE study)., PMID:40467307
Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study., PMID:40462321
Tertiary lymphoid structures signature predicts prognosis and clinical benefits from adjuvant chemotherapy and PD-L1 blockade in colorectal adenocarcinoma., PMID:40440077
The Importance of Timing in Immunotherapy: A Systematic Review., PMID:40416194
Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm, Multi-Centre Phase II Clinical Study., PMID:40415559
Neurological and Cardiac Adverse Events in Cervical Cancer Treatment: A Case of Postoperative Sintilimab-Induced Encephalitis and Myocarditis., PMID:40415286
Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report., PMID:40406249
Development of a lung immune prognostic index-based nomogram model for predicting overall survival and immune-related adverse events in non-small cell lung cancer patients treated with sintilimab., PMID:40406139
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study., PMID:40404633
Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review., PMID:40388765
Vitiligo-like rash in a patient with lung cancer caused by sintilimab: A case report., PMID:40385299
Sintilimab‑induced acute erosive hemorrhagic gastritis as an adverse reaction of third‑line therapy in a nasopharyngeal carcinoma patient: A case report., PMID:40370643
Use of sintilimab in primary adenosquamous carcinoma of the liver results in pathological complete response: a case report and literature review., PMID:40370460
Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials., PMID:40360867
Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study., PMID:40356893
Subacute cutaneous lupus erythematosus triggered by sintilimab: a case report., PMID:40342412
Pathological complete response after monotherapy with immune checkpoint inhibitors for bifocal colon cancer in a patient with lynch syndrome and situs inversus totalis: a case report., PMID:40330463
Prognostic value of the triglyceride-glucose index in advanced gastric cancer: A call for further exploration., PMID:40309236
Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer., PMID:40308504
Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder Sparing Surgery: A Phase 2 Trial., PMID:40302640
Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature., PMID:40290678
Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review., PMID:40271131
Esophageal squamous cell carcinoma with colonic and rectal metastases: a rare case report., PMID:40265024
Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis., PMID:40264761
The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study., PMID:40263352
Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial., PMID:40260253
Isolated Adrenocorticotropic Hormone Deficiency Associated with Sintilimab in the Treatment of Lung Adenocarcinoma: A Case Report and Literature Review., PMID:40257860
Combination Therapy of Transarterial Chemoembolization, Lenvatinib, and PD-1 Inhibitors Achieves Significant Tumor Response in Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report., PMID:40256770
Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report., PMID:40255433
Correction to "Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single-Arm Study"., PMID:40254725
Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective study., PMID:40252090
Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial., PMID:40251674
Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis., PMID:40247711
Long-term survival after chemotherapy combined immunotherapy for recurrent mixed neuroendocrine-non-neuroendocrine neoplasms of the common bile duct., PMID:40244371
Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report., PMID:40235902
Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study., PMID:40230857
Immunotherapy-associated autoimmune hemolytic anemia induced by anti-PD-1 therapy in esophageal cancer: A case report and literature review., PMID:40228248
Case Report: Esophageal cancer under comprehensive treatment strategy-application and clinical outcome analysis of combined immunotherapy, targeted therapy, and low-dose radiotherapy., PMID:40224180
Recombinant human‑endostatin combined with sintilimab and chemotherapy in first‑line treatment of locally advanced or metastatic esophageal squamous cell carcinoma., PMID:40182608
For research use only. Not for human or drug use.
